Alzheimer's decline may be slowed by protein boost
National outlets highlight UC published research
National media outlets including Newsweek and U.S. News & World Report highlighted UC research led by Alberto Espay that found new monoclonal antibody drugs for Alzheimer’s may slow cognitive impairment through boosting levels of the protein Aβ42 in the brain.
The research was published in the journal Brain Sept. 11.
For decades, the prevailing theory in the field has stated that a protein made up of 42 amino acids called amyloid-beta 42 (Aβ42) hardens into clumps called amyloid plaques, and those plaques in the brain cause the damage and/or dysfunction that causes Alzheimer’s disease.
Espay and team have hypothesized that normal, soluble Aβ42 in the brain is crucial for neuron health and that the loss of Aβ42, rather than the buildup of plaques, drives Alzheimer’s. This includes published research that suggests dementia occurs not when plaque levels are high but when Aβ42 levels drop very low.
"We noticed that most of the population with amyloid plaques does not develop Alzheimer's," Alberto Espay, professor of neurology at the University of Cincinnati Academic Health Center, told Newsweek. "By the age of 85 years, only one fifth of those with amyloid plaques develop Alzheimer's disease."
The team analyzed data from nearly 26,000 patients enrolled in 24 randomized clinical trials of new antibody treatments, assessing cognitive impairment and differences in levels of Aβ42 before and after treatment. They found that higher levels of Aβ42 after treatment were independently associated with slower cognitive impairment and clinical decline.
Espay said these findings fit well into his larger hypothesis about the root cause of Alzheimer’s, as increasing levels of Aβ42 appear to improve cognition.
"All stories have two sides—even the one we have told ourselves about how anti-amyloid treatments work: by lowering amyloid," Espay said. "In fact, they also raise the levels of Aβ42. Even if this is unintended, it is why there may be a benefit. Our study shows that we can predict changes in cognitive outcomes in anti-amyloid trials at least as well by the increases in Aβ42 as by the decreases in amyloid."
Read the U.S. News & World Report article, originally published on HealthDay.
Read the Yahoo News story, originally published on Fox News.
Read the Happiest Health article.
Featured photo at top of Alberto Espay. Photo/University of Cincinnati.
Related Stories
Cincinnati Children's LEND Program opens doors for UC graduate nursing students
June 9, 2026
UC graduate nursing students are broadening their expertise and career opportunities through the Cincinnati Children's LEND Program.
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.